Trial Profile
Phase 2 clinical study of evaluation of efficacy of switch to eribulin chemotherapy in patients with locally advanced breast cancer or metastatic breast cancer who are not responsive to combination regimen of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) and continuation of TAC chemotherapy in responding patients to TAC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2014
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Dec 2014 New trial record